Harnessing the cGAS-STING pathway to potentiate radiation therapy: current approaches and future directions
Overview of cGAS-STING Signaling in the Tumor Microenvironment after Ionizing Radiation Exposure. Ionizing radiation (lightning bolt) results in cytoplasmic release of mitochondrial dsDNA immediately and nuclear dsDNA eventually through micronuclei formation during cell division. This cytosolic dsDNA may be degraded by TREX1, a cytoplasmic endonuclease. cGAS activation involves two molecules of dsDNA bind to a dimer of cGAS (2:2 binding), which allows cGAS to form cGAMP from AMP and GMP. cGAMP intracellularly can activate STING in the endoplasmic reticulum (ER), which can then recruit TBK1. This complex brings in and phosphorylates IRF3, which then homodimerizes and translocates to the nucleus, where it acts as a transcription factor for the production of type I interferons. STING can also act through the NF-κB pathway to lead to increased inflammatory cytokine production (e.g., TNF-α, IL-1, IL-6, IL-8). cGAMP may also exit the cell via connexins/gap junctions, membrane transporters (e.g., LRCC8, ABCC1), or extracellular vesicles. dsDNA may also be contained in extracellular vesicles. Extracellular cGAMP not contained in vesicles is exposed to possible degradation by ENNP1, an endonuclease. cGAMP may be taken up by cells in the microenvironment via connexins/gap junctions, membrane transporters (LRRC8, P2x7R, SCL46A, SCL19A1), or via uptake of extracellular vesicles. The cGAMP can activate STING in recipient cells, and dsDNA uptake can lead to STING activation through recipient cell cGAS activation. This results in the paracrine/autocrine production of type I interferons and inflammatory cytokines in the tumor microenvironment. While the irradiated cell in this schematic was set to be a tumor cell, other irradiated cells in the tumor microenvironment (e.g., immune and stromal cells) may undergo similar cGAS-STING pathway signaling. Created with BioRender.com.
Publication
Harnessing the cGAS-STING pathway to potentiate radiation therapy: current approaches and future directions. (2024) Nicholas W. Colangelo, et al. Front Pharmacol. 2024;15:1383000. Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | STING | STING | ncbigene_synonym | STING1 | 340061 |
| Homo sapiens | Primates | CGAS | CGAS | ncbigene_symbol | CGAS | 115004 |
| Homo sapiens | Primates | Gap | GAP | ncbigene_synonym | RASA1 | 5921 |
| Homo sapiens | Primates | Gap | GAP | ncbigene_synonym | RGS6 | 9628 |
| Homo sapiens | Primates | AMP | AMP | ncbigene_synonym | APRT | 353 |
| Homo sapiens | Primates | AMP | AMP | ncbigene_synonym | MFAP1 | 4236 |
| Homo sapiens | Primates | GMP | GMP | ncbigene_synonym | NT5C2 | 22978 |
| Homo sapiens | Primates | LRRC8 | LRRC8 | ncbigene_synonym | LRRC8A | 56262 |
| Homo sapiens | Primates | LRRC8 | LRRC8 | famplex_relations | LRRC8B | 23507 |
| Homo sapiens | Primates | LRRC8 | LRRC8 | famplex_relations | LRRC8C | 84230 |
| Homo sapiens | Primates | LRRC8 | LRRC8 | famplex_relations | LRRC8D | 55144 |
| Homo sapiens | Primates | LRRC8 | LRRC8 | famplex_relations | LRRC8E | 80131 |
| Homo sapiens | Primates | SLC19A1 | SLC19A1 | ncbigene_symbol | SLC19A1 | 6573 |
| Homo sapiens | Primates | ABCC1 | ABCC1 | ncbigene_symbol | ABCC1 | 4363 |
| Homo sapiens | Primates | TBK1 | TBK1 | ncbigene_symbol | TBK1 | 29110 |
| Homo sapiens | Primates | IRF3 | IRF3 | ncbigene_symbol | IRF3 | 3661 |
| Homo sapiens | Primates | IFN | IFN | ncbigene_synonym | IFNA1 | 3439 |
| Homo sapiens | Primates | NFKB | NFKB | ncbigene_synonym | NFKB1 | 4790 |
| Homo sapiens | Primates | NFKB | NFKB | famplex_relations | RELA | 5970 |
| Homo sapiens | Primates | NFKB | NFKB | famplex_relations | RELB | 5971 |
| Homo sapiens | Primates | NFKB | NFKB | famplex_relations | REL | 5966 |
| Homo sapiens | Primates | NFKB | NFKB | famplex_relations | NFKB2 | 4791 |
| Homo sapiens | Primates | IKK | IKK | famplex_relations | CHUK | 1147 |
| Homo sapiens | Primates | IKK | IKK | famplex_relations | IKBKB | 3551 |
| Homo sapiens | Primates | IKK | IKK | famplex_relations | IKBKG | 8517 |
| Homo sapiens | Primates | IKK | IKK | famplex_relations | IKBKE | 9641 |
| Homo sapiens | Primates | Act | ACT | ncbigene_synonym | SERPINA3 | 12 |
| Homo sapiens | Primates | Act | ACT | ncbigene_synonym | ACTG1 | 71 |
| Homo sapiens | Primates | Act | ACT | ncbigene_synonym | ACTG2 | 72 |
| Homo sapiens | Primates | Act | ACT | ncbigene_synonym | FHL5 | 9457 |
| Homo sapiens | Primates | Act | ACT | ncbigene_synonym | ACOT7 | 11332 |
| Homo sapiens | Primates | Act | ACT | ncbigene_synonym | ACTBL2 | 345651 |
| Homo sapiens | Primates | Act | ACT | ncbigene_synonym | POTEKP | 440915 |
| Homo sapiens | Primates | Act | ACT | ncbigene_synonym | POTEM | 641455 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Nucleus | nucleus | nucleus | chebi:33252 | |
| DNA | DNA | deoxyribonucleic acids | chebi:16991 | |
| AMP | AMP | 5'-O-phosphonatoadenosine | chebi:456215 | |
| GMP | GMP | 5'-O-phosphonatoguanosine | chebi:58115 | |
| Nucleus | nucleus | nucleus | chebi:33252 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|